Watching ImmunityBio, Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsFinancial ResultsItem 2.02 · 8-KLOW RiskNeutral
ImmunityBio, Inc.
nantkwest.comFiled: Aug 4, 2026San Diego, CACIK: 0001326110Biotechnology
AI Executive Summary
AI-powered analysis of 8-K filing content
ImmunityBio announced Q2 2026 financial results and a business update on August 4, 2026, providing investors with an overview of the company's operational and financial position as of June 30, 2026.
Key Takeaways
Company released Q2 2026 financial results covering the three and six months ended June 30, 2026
Business update includes operational insights and financial position assessment as of mid-year 2026
2 more takeaways
Filing Overview
Form Type8-K
Filing DateAug 4, 2026
Item2.02
CategoryFinancial Results
CIK0001326110
Accession #ibrx-20260804
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings
What This Means
The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.